Since the first report of PR3-ANCA in IBD in 1989 [4], several studies have reported this biomarker in a significant percentage of IBD patients, both adults and children, and clinical utility for the management of IBD has been proposed. The gene discussed is PRTN3; the disease is inflammatory bowel disease.